Combining Paracentral Acute Middle Maculopathy and Peripapillary Fluid as Biomarkers in Anterior Ischemic Optic Neuropathy - 13/02/25
, Michael Stormly Hansen 1, 2, Lea Lykkebirk 1, 2, Yousif Subhi 1, 3, Jane Maestri Brittain 4, Mads Radmer Jensen 5, Uffe Møller Døhn 6, Viktoria Fana 6, Anne Katrine Wiencke 1, 2, Steffen Heegaard 1, 2, 7, Lene Terslev 2, 6, Steffen Hamann 1, 2Résumé |
PURPOSE |
To determine if paracentral acute middle maculopathy (PAMM) and peripapillary intraretinal and subretinal fluid (IRF/SRF) could help distinguish between arteritic anterior ischemic optic neuropathy (A-AION) and nonarteritic AION (NA-AION) at an early stage.
DESIGN |
Nested prospective cross-sectional diagnostic accuracy study.
METHODS |
This study used single-center optical coherence tomography (OCT) data from 8 patients with A-AION and 24 patients with NA-AION from two prospective cross-sectional studies with consecutive sampling (ClinicalTrials.gov: NCT05248906 and NCT05305079). The diagnosis of A-AION was based on expert interpretation of biochemical markers of inflammation, temporal artery biopsy and positron emission tomography/computed tomography. The diagnosis of NA-AION was made in cases without suspicion or clinical evidence of A-AION and with confirmed neuroophthalmological expert diagnosis. For this substudy patients were also required to have an OCT scan in relation to the diagnosis of AION. Macular OCT scans were graded by two independent, masked graders for the presence of PAMM and for IRF/SRF. The extension of IRF/SRF was assessed using an Early Treatment Diabetic Retinopathy Study (ETDRS) grid.
RESULTS |
PAMM was found in 50% of patients with A-AION and in 0% of patients with NA-AION ( P = .0019). In the setting of AION, the sensitivity of PAMM for the diagnosis of A-AION was 50% (95% CI: 16%-84%) while the specificity was 100% (95% CI: 86%-100%). Conversely, peripapillary IRF/SRF with extension into the ETDRS grid was observed in 83% of patients with NA-AION but in 0% of patients with A-AION ( P = .000047). The sensitivity of central macula-involving IRF/SRF for the diagnosis of NA-AION was 83% (95% CI: 63%-95%), while the specificity was 100% (95% CI: 63%-100%). Combining the two biomarkers, 75% of patients with AION could be classified based on OCT alone.
CONCLUSION |
PAMM appears to be a biomarker of A-AION while extensive peripapillary fluid appears to be a biomarker of NA-AION. Combining OCT biomarkers might allow for early classification of AION and warrants further prospective studies.
Le texte complet de cet article est disponible en PDF.Plan
| Supplemental Material available at AJO.com . |
|
| Meeting Presentation: Presented at the North American Neuro-Ophthalmological Society, Honolulu, Hawaii, March 2024. |
Vol 271
P. 329-336 - mars 2025 Retour au numéro
Article précédent
- Clinical Classification and Management Outcomes of Anterior Segment-Dominated Persistent Fetal Vasculature: The CCPMOH Report
- Hui Chen, Wan Chen, Fengqi Zhou, Chaokun Luo, Zhuoling Lin, Xiaoyan Li, Yongbin Lin, Haotian Lin, Weirong Chen
- Accuracy of 7 Artificial Intelligence–Based Intraocular Lens Power Calculation Formulas in Extremely Long Caucasian Eyes
- Wiktor Stopyra, Oleksiy Voytsekhivskyy, Andrzej Grzybowski
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?